{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-000438","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.157351+00:00","generated_at":"2026-05-24T20:23:22.265471+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vivani plans Cortigent spin-off, reports $18.4M cash; LIBERATE-1 trial fully enrolled with first implant","bullets":["Spin-off of Cortigent into independent public company planned by mid-2025; expects tax-free distribution to Vivani shareholders.","Cortigent's Orion artificial vision device completed 6-year study; Argus II previously FDA-authorized for blindness.","LIBERATE-1 trial of GLP-1 implant NPM-115: first implant administered, all 24 subjects enrolled in 4 weeks; top-line data expected mid-2025.","Preliminary cash and cash equivalents (excluding restricted) as of Dec 31, 2024: $18.4M (unaudited).","ThinkEquity LLC acting as financial advisor to Cortigent for spin-off."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-000438","json":"https://secwatch.observer/filing/0001753926-25-000438.json","markdown":"https://secwatch.observer/filing/0001753926-25-000438.md","text":"https://secwatch.observer/filing/0001753926-25-000438.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625000438/0001753926-25-000438-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625000438/vani-20250313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T20:23:22.265471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}